跳到正文
原文
Nature 健康护理主题·· 8 天前精选AI 评分80

RSV疫苗大幅降低感染:数据证明疫苗的惊人成功

RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus

AI 导读

丹麦自2025年10月起在全国范围内为孕妇接种RSV疫苗,新生儿住院率显著下降。全球范围内,RSV每年导致约360万儿童住院,其中97%发生在低收入和中等收入国家。疫苗和抗体治疗正在推广,有助于降低老年人和儿童的住院率和死亡率。

推荐理由

展示了RSV疫苗在降低住院率方面的显著效果,强调了在低收入国家推广疫苗的重要性。

正文 · 原文
A vial of respiratory syncytial virus vaccine, with a needle lying nex to it.

Protection against the respiratory syncytial virus (RSV) must expand to lower-income countries, which are harder hit.Credit: Hailshadow/Getty

“Something’s wrong with the data. There are too few people in hospitals” with respiratory syncytial virus (RSV), epidemiologist Caroline Klint Johannesen recalls a colleague remarking while analysing Danish health records for last winter.

On 1 October 2025, Denmark introduced a nationwide policy of vaccinating pregnant people against RSV — a respiratory pathogen that usually causes mild symptoms but can lead to severe disease and even death in vulnerable people, including infants and older adults. Maternal antibodies induced by the vaccine cross the placenta to protect babies for around the first six months of their lives, when they are most at risk. Newborns at high risk of severe disease, including premature infants, whose mothers had not been vaccinated, were given injections of monoclonal antibodies.

RSV wave hammers hospitals — but vaccines and treatments are coming

Johannesen, a vaccine researcher at Nordsjællands Hospital in Hillerød, Denmark, found1 that infant hospital admissions plummeted. The immunizations are working, she says (see ‘Newborn protection’).

Global risks

The World Health Organization (WHO) estimates that every year, RSV hospitalizes roughly 3.6 million and kills about 100,000 children under 5 years old. Of these deaths, 97% occur in low- and middle-income countries (LMICs).

The virus is also dangerous to older adults — although those risks are widely underappreciated by both physicians and the public. Historically, testing has been sparse, and there are no global statistics for RSV-related adult deaths. But over the age of 60, hospitalizations and mortality increase with age, especially in people with other diseases such as chronic heart and lung conditions. In the United States, the Centers for Disease Control and Prevention (CDC) estimates that between around 10,000 and 25,000 people have died in each of the past two winters, especially in older age groups.

Newborn protection. Line chart showing weekly hospital admissions in Denmark for newborns protected babies aged 5 months and under for RSV from 2016 to 2026. Disruption caused by the COVID-19 pandemic and the start of the immunization programme in 2025 can be seen. The chart shows that a combination of maternal vaccination (which 72% of eligible people took up) and antibody provision protected newborn babies.

Source: Ref. 1

Since 2022, when European regulators approved nirsevimab — a long-acting monoclonal antibody against RSV — a second antibody and three vaccines have been developed for use in adults, one of which is suitable for pregnant people.

“It’s just remarkable,” says Buddy Creech, a paediatrician at Vanderbilt University in Nashville, Tennessee, to have gone “from no mechanism to prevent RSV to an embarrassment of riches”. Dozens of countries across Europe, Asia and North and South America have launched various immunization programmes.

Up-to-date immunizations

来源:Nature 健康护理主题 · nature.com